Integrated Healthcare Data And AI Will Revolutionize Life Sciences

Published
26 Jan 25
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$5.00
64.6% undervalued intrinsic discount
20 Aug
US$1.77
Loading
1Y
-29.8%
7D
-11.5%

Author's Valuation

US$5.0

64.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on09 Apr 25
Fair value Decreased 9.09%

Shared on02 Apr 25
Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Decreased 0.60%

AnalystConsensusTarget has decreased revenue growth from 24.0% to 10.8%, decreased profit margin from 14.1% to 12.2%, increased future PE multiple from 32.2x to 57.9x and decreased shares outstanding growth rate from 0.0% to -0.0%.